Case Report

Erythrocytosis due to *PHD2* Mutations: A Review of Clinical Presentation, Diagnosis, and Genetics

Rachel Wilson,¹ Nausheen Syed,¹ and Prabodh Shah²

¹Chicago Medical School, North Chicago, IL, USA

²Little Company of Mary Hospital, Evergreen Park, IL, USA

Correspondence should be addressed to Rachel Wilson; wilson.rachel094@gmail.com

Received 8 November 2015; Revised 8 February 2016; Accepted 10 February 2016

Academic Editor: Stephen Langabeer

Copyright © 2016 Rachel Wilson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The association of mutations in the *PHD2* protein of the hypoxia-sensing pathway and erythrocytosis has only been established in the last decade. Here we report the case of a novel *PHD2* gene mutation in a patient with erythrocytosis and summarize all reported cases to date. *Case Report.* A 55-year-old man presented with dyspnea and a previous diagnosis of idiopathic erythrocytosis. *PHD* gene sequencing revealed a mutation on exon 2. The mutation was recognized as p.(Trp334*) (c. 1001G>A) resulting in a truncation of a highly conserved amino acid residue in catalytic domain. A diagnosis of erythrocytosis secondary to mutant *PHD2* gene was made. *Conclusions.* Our findings indicate that with *PHD2* mutations there is moderate erythrocytosis and erythropoietin (Epo) levels are generally low to normal. Two patients with *PHD2* substitution mutations were found to have paraganglioma and one of these patients had a concurrent pheochromocytoma. In addition, one mutation was associated with sagittal sinus thrombosis. Given the severity of some of the clinical features of these mutations, we conclude that clinical guidelines should include the *PHD2* mutation in the idiopathic erythrocytosis workup.

1. Introduction

The human body is intricately adapted to respond to low oxygen states. Hypoxia activates the hypoxia-inducible factor (HIF) pathway resulting in an increased production of erythropoietin (EPO) which, in turn, activates red blood cell production by binding receptors on erythroid progenitor cells. The HIF pathway includes the HIF- α transcription factor, the prolyl hydroxylase domain (PHD) protein family, and von Hippel-Lindau tumor suppressor protein (pVHL). There are three major isoforms of the PHD protein that are capable of binding HIF- α , but *PHD2* has been shown to be the most critical protein taking part in the oxygen-sensing pathway [1]. Under conditions of normal oxygen tension, the PHD proteins hydroxylate HIF- α allowing for the binding of the pVHL protein. Upon binding HIF- α , pVHL forms an E3 ubiquitin ligase complex which allows for HIF- α ubiquitination and subsequent degradation by a proteasome. However, under hypoxic conditions, *PHD2* reduces hydroxylation of HIF- α , allowing HIF- α to escape ubiquitin mediated degradation. Subsequently, HIF- α acts

as a transcription factor and upregulates expression of *EPO* gene resulting in increased EPO production. EPO is released into the bloodstream, binds to the Epo receptor (EpoR), and promotes growth and differentiation of erythroid precursors in the bone marrow. This causes an increase in red blood cell mass to compensate for the hypoxic condition.

The association of hereditary erythrocytosis with mutations of the *PHD2* gene (also known as the *EGLN1* gene) has been previously reported [2]. The erythrocytosis occurs by the decreased binding ability of the *PHD2* protein and subsequent increased activity of HIF- α [3]. Upregulation of HIF- α increases red cell mass and may contribute to vascular proliferation and cell growth [4]. This can lead to complications such as pulmonary hypertension and thrombophlebitis [5]. There are also likely decreased interactions of the *PHD2* protein with other binding proteins that may contribute to erythropoiesis [6].

We report a patient with a novel *PHD2* gene mutation, p.(Trp334*), and review the literature with described *PHD2* gene mutations.

TABLE 1: Characteristics of patients with *PHD2* mutations and polycythemia.

Number	Age/sex ¹⁾	Hb (g/L)	EPO (IU/L)	Relevant clinical data	Mode of inheritance ²⁾	Associated mutations	Relation to protein structure	Protein changes and mutation (catalytic domain from amino acid residues 181–426 [15])	Reference
1	43 (44) M	202	24.0 (5–25)	N/A	N/A	Homozygous <i>JAK2</i> V617F	Substitution between N-terminal MYND zinc finger-like domain and conserved C-terminal catalytic domain	p.(Gln157His); c.471G>C	Ladrone et al. [6]
							Substitution between N-terminal MYND zinc finger-like domain and conserved C-terminal catalytic domain		
2	65 (65) M	171	29.0 (5–30)	Thrombocytosis, leukocytosis and splenomegaly, Phlebotomies, and hydroxycarbamide	Autosomal dominant	Homozygous <i>JAK2</i> V617F	Substitution between N-terminal MYND zinc finger-like domain and conserved C-terminal catalytic domain	p.(Gln157His); c.471G>C	Albiero et al. [16]
							Substitution between N-terminal MYND zinc finger-like domain and conserved C-terminal catalytic domain		
3	40 (40) M	170	8.0 (5–30)	N/A	Autosomal dominant	None	Substitution between N-terminal MYND zinc finger-like domain and conserved C-terminal catalytic domain	p.(Gln157His); c.471G>C	Albiero et al. [16]
							Substitution of highly conserved amino acid one residue from site that chelates Zn and Cd ions		
4	22 (34) M	179	90.0 (5–25)	N/A	N/A	None	Mutation causes delayed hydroxylation of HIF- α	p.(Pro200Gln); c.599C>A	Ladrone et al. [6]
							Truncation in catalytic domain of 154 C-terminal amino acids		
5	54 (54) M	192	20.0 (5–25)	Inflammatory arthralgia, visual symptoms, and phlebotomies	Autosomal dominant	None		p.(Met202Ilefs*72); c.606delG	Al-Sheikh et al. [17]

TABLE 1: Continued.

Number	Age/sex ¹¹	Hb (g/L)	EPO (IU/L)	Relevant clinical data	Mode of inheritance ⁸	Associated mutations	Relation to protein structure	Protein changes and mutation (catalytic domain from amino acid residues 181–426 [15])	Reference
6	>54 (>54) M	171	11.5 (5–25)	Phlebotomies	Autosomal dominant	None	Truncation in catalytic domain of 154 C-terminal amino acids	p.(Met202Ilefs*72); c.606delG	Al-Sheikh et al. [17]
7	61 (80) M	230	2.0 (5–25)	Hemorrhage, phlebotomy, and aspirin	N/A	JAK2-exon 12	Substitution of highly conserved part of catalytic site	p.(Asn203Lys); c.609C>G	Albiero et al. [18]
8	49 (46) M	200	11.0 (5–25)	Cardiac disease	N/A	None	Substitution of mutation of catalytic site	p.(Lys204Glu); c.610G>A	Bento et al. [19]
9	52 (51) M	183	8.13 (5–25)	Klinefelter's syndrome	N/A	None	Truncation mutation of catalytic site	p.(Gln221*); c.661C>T	Lambert, unpublished data (2013) [§]
10	34 (24) M	172	N/A	Headaches	N/A	None	Truncation mutation of catalytic site	p.(Arg227Alafs*20); c.678dupG	Bento and Almeida, unpublished data (2014) [§]
11	16 (60) F	160	40.5 (<31.5)	Red eyes, flushed cheeks and feet headache, episodic chest pain palpitations, and primary hyperparathyroidism cystic kidney disease paraganglioma pheochromocytoma repeated phlebotomies	N/A	None	Substitution of highly conserved residue site likely to affect protein folding and stability	p.(Ala228Ser); c.682G>T	Yang et al. [8]
12	52 (58) M	178	N/A		N/A	None	Truncation mutation of catalytic site	p.(Gln239*); c.715C>T	Bento and Almeida, unpublished data (2014) [§]
13	25 (48) M	192	2x normal (5–25)	N/A	N/A	None	Substitution of highly conserved residue of catalytic site	p.(Asp254His); c.760G>C	Ladrone et al. [6]

TABLE 1: Continued.

Number	Age/sex ¹¹	Hb (g/L)	EPO (IU/L)	Relevant clinical data	Mode of inheritance ⁸	Associated mutations	Relation to protein structure	Protein changes and mutation (catalytic domain from amino acid residues 181–426 [15])	Reference
14	73 (73) M	188	1.3 (10.2–28.5)	Smoker	N/A	None	Loss of catalytic activity of PHD2 protein	p.(Leu279Thrfs43*); c.835del4	Jang et al. [20]
15	22 (22) M	178	N/A	Tinnitus	N/A	None	Truncation of 143 C-terminal amino acids	p.(Arg281Thrfs*3); c.840_841insA	Al-Sheikh et al. [17]
16	68 (65) M	183	60 (5–25)		N/A	None	Substitution mutation of catalytic site	p.(Gly285Arg); c.853G>C	Bento et al. [19]
17	29 (38) M	176	5.0 (5–25)	N/A	Autosomal dominant	None	Substitution of nonconserved residue of catalytic domain	p.(Lys291Ile); c.872A>T	Albiero et al. [18]
18	48 (48) F	180	6.2 (5–25)	Leukoclastic vasculitis	N/A	None	Substitution mutation of catalytic site	p.(Pro304Leu); c.911C>T	Percy and McMullin, unpublished data (2004) [§]
19	45 (45) M	180	N/A	Smoker with intermittent claudication and death from esophageal carcinoma	Autosomal dominant	None	Substitution of highly conserved amino acid, close proximity to site responsible for coordinating Fe ²⁺ at active site	p.(Pro317Arg); c.950C>G	Percy et al. [2]
20	26 (26) F	180	6.3 (5–25)	Superficial thrombophlebitis, history of menorrhagia, and phlebotomies	Autosomal dominant	None	Substitution of highly conserved amino acid, close proximity to site responsible for coordinating Fe ²⁺ at active site	p.(Pro317Arg); c.950C>G	Percy et al. [2]
21	30 (30) M	175	6.4 (5–25)	Paresthesia, absent left kidney, and enlarged right kidney	Autosomal dominant	None	Substitution of highly conserved amino acid, close proximity to site responsible for coordinating Fe ²⁺ at active site	p.(Pro317Arg); c.950C>G	Percy et al. [2]

TABLE 1: Continued.

Number	Age/sex ¹¹	Hb (g/L)	EPO (IU/L)	Relevant clinical data	Mode of inheritance ⁵	Associated mutations	Relation to protein structure	Protein changes and mutation (catalytic domain from amino acid residues 181–426 [15])	Reference
22	31 (31) F	174	6.0 (3–34)	N/A	Autosomal dominant	None	Substitution of highly conserved amino acid of catalytic domain	p.(Trp334Arg); c.1000T>C	Bento et al. [21]
23	49 (55) M	215	8.3 (4–16)	Phlebotomies	Sister has polycythemia	None	Truncation in highly conserved amino acid residue in catalytic domain	p.(Trp334*); c.1001G>A	(this paper)
24	35 (35) F	178	10.7 (5–25)	Phlebotomies	N/A	None	Truncation of 50 C-terminal amino acids	p.(Gln337*); c.1129C>T	Al-Sheikh et al. [17]
25	21 (24) M	171	9.9 (5–25)	TIA	N/A	None	Truncation mutation of catalytic site	p.(Val338Glyfs*18); c.1010dup	Bento et al. [19]
26	47 (47) M	168	9.5 (5–25)		N/A	None	Substitution mutation of catalytic site	p.(Arg371Cys); c.1111C>T	Percy and McMullin, unpublished data (2013) [§]
27	17 (25) M	191	Normal (5–25)	N/A	N/A	None	Substitution of highly conserved amino acid 3 residues away from Fe ²⁺ chelating residue	p.(Arg371His); c.1112G>A	Ladrone et al. [6]
28	29 (38) M	188	12.0 (5–25)	Sagittal sinus thrombosis and phlebotomies	N/A	None	Substitution of highly conserved amino acid 3 residues away from Fe ²⁺ chelating residue	p.(Arg371His); c.1112G>A	Percy et al. [3]
29	30 (43) M	202	18.0 (5–25)	Recurrent para-aortic paraganglioma hypertension phlebotomies	N/A	Homozygous C282Y mutation	Substitution of highly conserved amino acid critical to coordinating Fe ²⁺ binding	p.(His374Arg); c.1121A>G	Ladrone et al. [12]
30	64 (67) F	161	N/A	Suspected liver and renal angiodomas	Autosomal dominant	None	Truncation in catalytic domain	p.(Arg398*); c.1192C>T	Ladrone et al. [6]

TABLE 1: Continued.

Number	Age/sex	Hb (g/L)	EPO (IU/L)	Relevant clinical data	Mode of inheritance [§]	Associated mutations	Relation to protein structure	Protein changes and mutation (catalytic domain from amino acid residues 181–426 [15])	Reference
31	26 (41) M	193	6.5 (5–25)	N/A	Autosomal dominant	None	Truncation in catalytic domain	P.(Arg398 [*]); c.1192C>T	Ladrone et al. [6]
32	60 (80) M	164	23.0 (5–25)	Treated with aspirin and phlebotomies	N/A	None	Substitution of highly conserved residue mutation of catalytic domain	P.(Lys423Glu); c.1267A>G	Albiero et al. [18]

^{||} Age at diagnosis (age at workup for mutation).

[§] Original sources listed, data later compiled in review by Gardie et al. [22]

^{*} Mode of inheritance determined by family history.

Our patient presented to our clinic in 2014 at the age of 55 with recent onset of mild dyspnea and a diagnosis of erythrocytosis since 2009. His medical history included hypertension, hyperlipidemia, sleep apnea, atrial fibrillation, and type 2 diabetes mellitus. His medications included furosemide, enalapril, simvastatin, warfarin, aspirin, digoxin, and metformin. He was a nonsmoker. He was treated with phlebotomies in the past and his hemoglobin values had fluctuated from 180 g/L to 215 g/L. His sister had hemoglobin of 162 g/L. Otherwise family history was unremarkable.

Physical exam included temperature of 36.9°C, blood pressure of 127/79 mmHg, pulse rate of 60 beats per minute, and respiratory rate of 12 breaths per minute. Findings included a mildly ruddy complexion, lungs clear to auscultation bilaterally, and irregular heart tones. There was neither hepatosplenomegaly nor masses. Extremities revealed no edema and lymph node exam was unremarkable. Neurological exam was normal.

Investigations showed red cells count was $7.41 \times 10^{12}/L$, hemoglobin was 194 g/L, white blood cell count was $6.5 \times 10^9/L$, and platelet count was $255 \times 10^9/L$. The oxygen saturation was 98%, nocturnal oxygen saturation remained above 92%, carboxyhemoglobin was 2.3%, and no abnormal hemoglobin was detected on electrophoresis or isoelectrofocusing. The P_{50} was 28 mmHg (24–30 mmHg) and erythropoietin was 8.3 IU/L (4.0–16.0 IU/L). CT scan did not show splenomegaly or intra-abdominal masses suspicious for tumors.

Bone marrow aspirate showed normal maturation and iron stores were present. Cytogenetic analysis did not reveal any abnormal karyotype. *JAK2*^{V617F} mutation was not identified on exon 14; neither were *JAK2* mutations found for exons 8 or 12. *HIF-2 α* (*EPAS1*) and *EPOR* gene sequencing did not reveal any mutations. However, *PHD* gene sequencing revealed a mutation on exon 2. The mutation was recognized as p.(Trp334*) (c. 1001G>A). A diagnosis of erythrocytosis secondary to mutant *PHD2* gene was made.

Currently, the patient remains asymptomatic.

2. Discussion

Patients included in this review had erythrocytosis and mutations of the *PHD2* gene resulting in loss of function of PHD2 proteins. Familial cases suggest autosomal dominant inheritance whereas the isolated cases are likely sporadic germline mutations. There are twenty-five different mutations reported of the *PHD2* gene: fifteen substitutions, five nonsense mutations, and five frameshift mutations. Most mutations involve evolutionarily conserved residues that influence protein catalytic activity (see Table 1).

In the HIF pathway, erythrocytosis associated with HIF and VHL proteins is associated with high EPO levels [7]. However, our findings indicate that, with *PHD2* gene mutations, EPO levels are generally low to normal. In our review, twenty-one patients had normal EPO levels, four patients had unexplained elevated levels, two had a low level, and the rest were unknown. The low-normal EPO level in the face of erythrocytosis in *PHD2* mutants likely involves heightened

expression and sensitivity of EPO receptor and HIF regulation [8]. The heightened EpoR sensitivity and expression are presumably a result of PHD2's regulation of HIF and PHD2's interaction with other binding proteins besides HIF [6].

The association of tumorigenesis and germline mutations of proteins in hypoxia-sensing pathway has already been well established [9, 10]. The most well-known syndrome to associate erythrocytosis and tumorigenesis is von Hippel Lindau disease, but mutations in *PHD1* and *HIF2 α* (*EPAS1*) are also implicated in tumorigenesis [8, 11]. In our review, we found two patients with *PHD2* substitution mutations who had paragangliomas and one of these patients had a concurrent pheochromocytoma [8, 12]. Furthermore, *PHD2* germline mutations can have oncogenic potential in vitro [13] and analysis of paraganglioma cells suggests *PHD2* may have tumor suppressor activity since the tumor cells showed loss of heterozygosity of wild-type *PHD2* allele [6]. Suppression of tumor growth may be related to the *PHD2* gene's regulation of various cytokines [14]. These observations suggest that therapeutic guidelines regarding the diagnostic workup of idiopathic erythrocytosis need to consider the possibility of these autosomal dominant mutations and may benefit the family members by providing early detection of tumors. In addition, the association of a *PHD2* substitution mutation and sagittal sinus thrombosis warrants search for thrombotic risks of such mutations [3].

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] E. Berra, E. Benizri, A. Ginouvès, V. Volmat, D. Roux, and J. Pouyssegur, "HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 α in normoxia," *The EMBO Journal*, vol. 22, no. 16, pp. 4082–4090, 2003.
- [2] M. J. Percy, Q. Zhao, A. Flores et al., "A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 3, pp. 654–659, 2006.
- [3] M. J. Percy, P. W. Furlow, P. A. Beer, T. R. J. Lappin, M. F. McMullin, and F. S. Lee, "A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove," *Blood*, vol. 110, no. 6, pp. 2193–2196, 2007.
- [4] P. H. Maxwell, G. U. Dachs, J. M. Gleadow et al., "Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 15, pp. 8104–8109, 1997.
- [5] R. Hu, A. Dai, and S. Tan, "Hypoxia-inducible factor 1 α upregulates the expression of inducible nitric oxide synthase gene in pulmonary arteries of hypoxic rat," *Chinese Medical Journal*, vol. 115, no. 12, pp. 1833–1837, 2002.
- [6] C. Ladroue, D. Hoogewijs, S. Gad et al., "Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia," *Haematologica*, vol. 97, no. 1, pp. 9–14, 2012.

- [7] M. McMullin, "Idiopathic erythrocytosis: a disappearing entity," *Hematology/the Education Program of the American Society of Hematology*, vol. 2009, no. 1, pp. 629–635, 2009.
- [8] C. Yang, Z. Zhengping, S. Fliedner, U. Shankavaram, M. Sun, and P. Bullova, "Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia," *Journal of Molecular Medicine*, vol. 93, no. 1, pp. 93–104, 2015.
- [9] E. R. Maher, H. P. H. Neumann, and S. Richard, "Von Hippel-Lindau disease: a clinical and scientific review," *European Journal of Human Genetics*, vol. 19, no. 6, pp. 617–623, 2011.
- [10] N. J. Mabjeesh and S. Amir, "Hypoxia-inducible factor (HIF) in human tumorigenesis," *Histology and Histopathology*, vol. 22, no. 5, pp. 559–572, 2007.
- [11] C. Yang, M. G. Sun, J. Matro et al., "Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas," *Blood*, vol. 121, no. 13, pp. 2563–2566, 2013.
- [12] C. Ladroue, R. Carcenac, M. Leporrier et al., "PHD2 mutation and congenital erythrocytosis with paraganglioma," *The New England Journal of Medicine*, vol. 359, no. 25, pp. 2685–2692, 2008.
- [13] K. Lee, J. D. Lynd, S. O'Reilly, M. Kiupel, J. J. McCormick, and J. J. LaPres, "The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential," *Molecular Cancer Research*, vol. 6, no. 5, pp. 829–842, 2008.
- [14] S. Mamlouk, J. Kalucka, R. P. Singh et al., "Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development," *International Journal of Cancer*, vol. 134, no. 4, pp. 849–858, 2014.
- [15] M. A. McDonough, V. Li, E. Flashman et al., "Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 26, pp. 9814–9819, 2006.
- [16] E. Albiero, M. Ruggeri, S. Fortuna et al., "Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation," *British Journal of Haematology*, vol. 153, no. 3, pp. 405–408, 2011.
- [17] M. Al-Sheikh, K. Moradkhani, M. Lopez, H. Wajcman, and C. Préhu, "Disturbance in the HIF-1 α pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene," *Blood Cells, Molecules, and Diseases*, vol. 40, no. 2, pp. 160–165, 2008.
- [18] E. Albiero, M. Ruggeri, S. Fortuna et al., "Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene," *Haematologica*, vol. 97, no. 1, pp. 123–127, 2012.
- [19] C. Bento, M. J. Percy, B. Gardie et al., "Genetic basis of congenital erythrocytosis: mutation update and online databases," *Human Mutation*, vol. 35, no. 1, pp. 15–26, 2014.
- [20] J.-H. Jang, J. Y. Seo, J. Jang et al., "Hereditary gene mutations in Korean patients with isolated erythrocytosis," *Annals of Hematology*, vol. 93, no. 6, pp. 931–935, 2014.
- [21] C. Bento, H. Almeida, T. M. Maia et al., "Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (where is/are the missing gene(s)?)," *European Journal of Haematology*, vol. 91, no. 4, pp. 361–368, 2013.
- [22] B. Gardie, M. J. Percy, D. Hoogewijs et al., "The role of PHD2 mutations in the pathogenesis of erythrocytosis," *Hypoxia*, vol. 2014, no. 2, pp. 71–90, 2014.